Chimeric Therapeutics Limited (ASX: CHM), an innovative Australian firm specializing in cell therapy, has commenced a Phase 1B clinical trial for the treatment of recurrent or progressive glioblastoma multiforme (GBM) employing CHM 1101 CAR T cell therapy. Building upon promising results from the Phase 1A study, this Phase 1B trial focuses on patients with glioblastoma. The groundbreaking CHM 1101, an autologous Chlorotoxin CAR T cell therapy, is precisely tailored for those experiencing recurrent and/or advancing glioblastoma.
The innovative CHM 1101, a personalized Chlorotoxin CAR T cell therapy, is custom-designed for patients grappling with recurring or advancing glioblastoma. Administered as a second-line therapy, the patient received CHM 1101 treatment, reflecting a significant step forward in advancing novel therapies for glioblastoma. This development highlights Chimeric Therapeutics' dedication to pioneering cutting-edge treatments in the fight against challenging brain cancers.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
